Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.66 USD | -4.47% | -6.91% | +23.87% |
May. 08 | Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating | MT |
May. 08 | Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.87% | 1.99B | B- | ||
-2.26% | 181B | C+ | ||
+2.05% | 108B | C | ||
-1.31% | 69.41B | A | ||
+14.65% | 46.61B | B- | ||
-6.69% | 45.85B | B- | ||
+7.97% | 42.61B | B+ | ||
+18.60% | 30.71B | B | ||
+16.92% | 25.63B | A- | ||
-6.87% | 23.32B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STAA Stock
- Ratings STAAR Surgical Company